Opinion|Videos|November 4, 2024
Pathophysiology and Standard of Care in Generalized Myasthenia Gravis
Key Takeaways
- MG involves antibodies targeting acetylcholine receptors, disrupting neuromuscular transmission and causing muscle weakness.
- New therapeutic targets include MuSK and LRP4, offering potential for novel treatment strategies.
Panelists discuss how the current understanding of myasthenia gravis pathophysiology is informing the development of targeted treatments, alongside reviewing the standard of care for generalized myasthenia gravis (gMG).
Advertisement
Video content above is prompted by the following:
- What is our current understanding of the underlying pathophysiology of MG? How is this being utilized to design targeted agents to treat gMG?
- What is the standard of care for gMG?
Advertisement
Related to this article
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
3
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
4
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
5